National program establishes early care management, technology innovation and large health system engagement as a strategic priority for supporting the 34 million U.S. individuals living with diabetes

Renalytix reported financial results for the quarter ended September 30, 2021.

Leading clinicians discuss enabling long-term kidney health in Veterans with type 2 diabetes and early-stage chronic kidney disease

Partnership expands doctor and patient access to advanced prognosis and coordinated care management of early-stage diabetic kidney disease

Renalytix recently announced its results for the twelve months ended 30 June 2021.

Levangie brings extensive commercial operating experience to Renalytix, served on boards of Exact Sciences, Insulet Corporation and Hologic.